Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Christopher Vanderhook, Viant Technology's COO and substantial shareholder, conducted an indirect sale of 12,500 Class A shares, generating proceeds of approximately $153,129. Concurrently, the company reported impressive Q3 2025 financial results and unveiled a new collaboration with iHeartMedia to enhance programmatic advertising capabilities acr…
Capital V LLC, holding a 10% stake in Viant Technology Inc., sold 37,500 shares of Class A Common Stock totaling approximately $459,389 between January 20 and January 22, 2026. Viant Technology recently reported robust third-quarter earnings surpassing analyst estimates and unveiled a programmatic advertising partnership with iHeartMedia. Analyst f…
The U.S. Justice Department has formally charged Aurelio Perez-Lugones, a 61-year-old contractor employee, with unlawful transmission and retention of classified military information. The case is linked to sensitive materials being shared with a Washington Post journalist, prompting a search of the reporter's home and raising questions about press …
Coreweave's Chief Development Officer, Brannin McBee, recently sold 130,345 Class A shares valued at approximately $12.5 million, according to filings from January 20, 2026. The sales were undertaken through a Rule 10b5-1 trading plan and coincided with company developments including enhanced AI platform offerings and financial adjustments. Despite…
CoreWeave's Chief Development Officer Brannin McBee sold over 34,000 shares totaling approximately $3.3 million under a structured trading plan, reflecting a complex stock position management amid significant company developments including loan amendments and AI technology integration plans. The stock has experienced substantial annual gains despit…
Nintendo's stock surged on Friday in Tokyo following market data confirming the Switch 2 console as the leading video game hardware platform in the U.S. during 2025. Sales figures reveal the new console nearly doubling the original Switch’s installed base within seven months, bolstering market sentiment despite earlier concerns over consumer spendi…
Abeona Therapeutics Chief Executive Officer Vishwas Seshadri executed a sale of nearly 70,000 shares for $372,267 to address tax liabilities linked to restricted stock awards. The biopharmaceutical firm also reported a better-than-expected quarterly earnings performance, while making strategic appointments and expanding its gene therapy treatment f…
Joseph Walter Vazzano, CFO of Abeona Therapeutics Inc, sold over 18,600 shares to meet tax obligations following restricted stock vesting. This insider sale follows the company’s positive third-quarter financial report and advancements in its gene therapy treatment offerings. Industry analysts present mixed price targets, reflecting ongoing operati…
Brendan M. O’Malley, Senior Vice President and Chief Legal Officer at Abeona Therapeutics Inc., recently sold 13,578 shares worth approximately $72,382. The move occurred during a period marked by the company's stronger-than-expected earnings report, leadership changes, and shifts in analyst price targets. Abeona continues to maintain a solid liqui…
Fairmount Funds Management LLC, a director entity of Cogent Biosciences, executed a major sale of 3.5 million shares at $36.40 each, totaling $127.4 million on January 22, 2026. This transaction took place while Cogent’s stock approached its 52-week peak, reflecting exceptional growth. Despite the sale, the fund retains a substantial stake, and the…
Asia-Pacific stock markets saw modest increases on Friday during early trading as investors awaited the Bank of Japan's upcoming policy meeting, where rates are broadly expected to remain unchanged. The rally came amid a backdrop of diminishing US trade tensions following softer rhetoric from President Trump, alongside steady inflation data from Ja…
Mark N. Tompkins, holding a 10% stake in Aeluma Inc., divested approximately 104,638 shares of the company's common stock between January 20 and January 22, 2026, generating roughly $2 million in proceeds. This transaction occurred alongside the firm's Q1 FY2026 financial results, which revealed notable revenue growth but a slight miss on expected …
Fairmount Healthcare Fund II L.P. liquidated 1.75 million shares of Apogee Therapeutics common stock at $76.30 per share in January 2026, yielding approximately $133.5 million. This transaction took place near Apogee’s 52-week peak, against a backdrop of nearly doubling its stock value in the last year. Despite this strong price performance, some v…
The film 'Sinners' set a historic milestone by securing 16 Oscar nominations, surpassing previous records and positioning itself as a strong contender for Best Picture. The nominations highlight a broad spectrum of cinematic genres and showcase an Academy increasingly open to innovative storytelling. Key actors including Michael B. Jordan face nota…
Gerald L. Morgan, the CEO and Executive Vice Chairman of Texas Roadhouse Inc, sold 5,000 shares at $196 each on January 20, 2026, totaling $980,000. The sale took place close to the stock’s 52-week peak of $199.99, with shares stable at $191.25 currently. Texas Roadhouse maintains a robust financial stance, reflected in a 'GREAT' InvestingPro score…
Stitch Fix Chief Financial Officer David Aufderhaar sold 24,114 shares of Class A Common Stock on January 20, 2026, at $5.1264 per share, totaling $123,618. Despite the sale, Aufderhaar retains a substantial 1,251,862 shares. The company’s stock is currently slightly above the CFO’s sale price and is considered undervalued by InvestingPro’s Fair Va…
The U.S. dollar is set to experience its largest weekly decrease in a year, triggered by recent geopolitical developments including President Trump's statements on Greenland. Meanwhile, the Japanese yen remains under pressure as investors await the Bank of Japan's policy decision. Market participants are closely watching these dynamics amid concern…
ByteDance, TikTok's parent company, has reached an agreement to establish a U.S.-based joint venture with majority American ownership to address government concerns and avoid a ban on the widely used social media platform. The move follows years of scrutiny over national security risks associated with TikTok, which boasts over 200 million users in …
GigaCloud Technology Inc's CEO Wu Lei and related entities executed a series of share sales totaling approximately $892,140 between January 20 and 22, 2026. Despite these transactions, the company shows robust financial health, with strong quarterly earnings surpassing expectations and strategic moves including a recent acquisition. The sales were …
Kenneth Duda, President and CTO of Arista Networks, completed a substantial sale of nearly 30,000 shares and exercised stock options, amidst the company's rising share price and ongoing favorable analyst recommendations. Additional share sales by trusts linked to Duda highlight internal liquidity actions as the company prepares for its upcoming ear…
Elliot Dean Hoops, serving as General Counsel and Secretary for MP Materials Corp, finalized a stock sale valued at approximately $533,606, disposing of 7,823 shares at varied prices in late January 2026. This transaction adhered to a previously established Rule 10b5-1 trading schedule. Concurrently, MP Materials has reported important progress in …
Christopher Gibson, director at Recursion Pharmaceuticals, sold 40,000 shares of Class A Common Stock in January 2026, coinciding with a stock conversion of Class B to Class A shares. Meanwhile, the company disclosed promising interim results from its Phase 1b/2 TUPELO trial assessing the investigational drug REC-4881, showing substantial reduction…
Jonathan Zalevsky, Chief Research and Development Officer at biopharmaceutical company Nektar Therapeutics, sold 3,867 company shares worth approximately $137,935 at an average price of $35.67 on January 20, 2026. This transaction follows recent mixed results from Nektar's Phase 2b REZOLVE-AA trial for alopecia areata, which narrowly missed its pri…
Campbell Bradley L., the President and CEO of Amicus Therapeutics, completed a sale of 75,000 shares on January 20, 2026, generating approximately $1.07 million. Alongside this, he exercised options to acquire an equal number of shares. This insider activity coincides with a strong market performance for Amicus shares and the announcement of an all…
EverCommerce Inc. CEO Eric Richard Remer completed two stock sale transactions in late January 2026, liquidating approximately $171,000 in shares through a structured trading plan. The company recently announced third-quarter 2025 results reflecting slight revenue gains yet received cautious analyst reactions, highlighting a balanced risk landscape…
